HepCBC has been asked by CADTH* to do a Patient Group Review of the new INTERFERON-FREE drug combo sofosbuvir and ledipasvir
(also known as SOVALDI and GS-5885) for Chronic Hepatitis C, developed
by Gilead Sciences. We urgently request input from individual HCV+
people (both those who have and have not tried this drug combination,
For background info see http://hepcbc.ca/contribute-sofosbuvir-ledipasvir-submission-cadth/.
For the actual questionnaire, go to: http://hepcbc.ca/questions-cadth-sofosbuvir-ledipasvir/. DEADLINE: Sunday, October 5th, 2014.
Please tweet, re-tweet, put on Facebook, and forward this information, thanks!
*CADTH = Canadian Agency for Drugs and
Technologies in Health, which does government-requested reviews for
Health Canada and the Canadian Drug Review process.